CRISPR Therapeutics (CRSP) PT Lowered to $150 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $51.98 -4.2%
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Join SI Premium – FREE
JMP Securities analyst Silvan Tuerkcan lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $150.00 (from $155.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Amrize Ltd (AMRZ) PT Raised to $43 at DA Davidson
- Teck Resources Ltd (TECK) PT Raised to $72 at StoneX
- XPO (XPO) PT Raised to $235 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
